Formulary guidance and transparency from P&T to point of care


Reality Check on Acute Lymphoblastic Leukemia

Market access for acute lymphoblastic leukemia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 42% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In July 2021, the FDA approved Jazz Pharmaceuticals plc's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in pediatric and adult patients 1 month and older who are allergic to E. coli-derived asparaginase products
  • Key Findings: The first-line treatment for many of the variants of ALL is to enroll eligible patients into clinical trials. If this is not done, most medications require prior authorization. Most drugs are covered under either the pharmacy or medical benefit, and coverage is dependent upon the route of administration

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.